Eventide Asset Management LLC Has $44.22 Million Holdings in Abivax SA Sponsored ADR $ABVX

Eventide Asset Management LLC cut its position in Abivax SA Sponsored ADR (NASDAQ:ABVX) by 17.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 327,911 shares of the company’s stock after selling 68,993 shares during the period. Eventide Asset Management LLC owned 0.41% of Abivax worth $44,221,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. UBS Group AG raised its stake in shares of Abivax by 2,561.0% in the third quarter. UBS Group AG now owns 4,461,262 shares of the company’s stock worth $378,761,000 after acquiring an additional 4,293,606 shares during the last quarter. Darwin Global Management Ltd. bought a new position in shares of Abivax in the third quarter worth about $263,698,000. Morgan Stanley raised its stake in shares of Abivax by 114.3% in the fourth quarter. Morgan Stanley now owns 3,151,994 shares of the company’s stock worth $425,062,000 after acquiring an additional 1,681,277 shares during the last quarter. Paradigm Biocapital Advisors LP bought a new position in shares of Abivax in the third quarter worth about $132,800,000. Finally, TCG Crossover Management LLC raised its stake in shares of Abivax by 17.4% in the third quarter. TCG Crossover Management LLC now owns 7,111,596 shares of the company’s stock worth $603,774,000 after acquiring an additional 1,055,000 shares during the last quarter. 47.91% of the stock is currently owned by institutional investors and hedge funds.

Abivax Price Performance

ABVX opened at $96.55 on Friday. The company has a market cap of $7.69 billion, a price-to-earnings ratio of -18.53 and a beta of 0.69. The firm has a 50 day simple moving average of $116.01 and a 200 day simple moving average of $119.12. Abivax SA Sponsored ADR has a fifty-two week low of $5.69 and a fifty-two week high of $148.83.

Abivax (NASDAQ:ABVX) last posted its quarterly earnings results on Friday, May 22nd. The company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.23. The business had revenue of $1.56 million for the quarter, compared to the consensus estimate of $0.40 million. As a group, analysts expect that Abivax SA Sponsored ADR will post -3.4 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have weighed in on ABVX. BTIG Research reaffirmed a “buy” rating and issued a $150.00 target price on shares of Abivax in a research note on Tuesday, June 2nd. Wall Street Zen raised shares of Abivax from a “sell” rating to a “hold” rating in a research note on Saturday, May 23rd. Wolfe Research set a $136.00 target price on shares of Abivax in a research note on Wednesday, June 3rd. Wedbush raised shares of Abivax from an “underperform” rating to a “neutral” rating and dropped their target price for the stock from $110.00 to $90.00 in a research note on Tuesday, June 2nd. Finally, Jefferies Financial Group downgraded shares of Abivax from a “buy” rating to a “hold” rating and dropped their price target for the stock from $160.00 to $90.00 in a research note on Tuesday, June 2nd. Twelve analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $130.08.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.